國立虎尾科技大學 |

Targeting the DNA Damage Response for Anti-Cancer Therapy

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Targeting the DNA Damage Response for Anti-Cancer Therapy/ edited by John Pollard, Nicola Curtin.
other author:	Pollard, John.
Description:	IX, 401 p. 80 illus., 52 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Cancer research. -
Online resource:	https://doi.org/10.1007/978-3-319-75836-7
ISBN:	9783319758367

Targeting the DNA Damage Response for Anti-Cancer Therapy
Targeting the DNA Damage Response for Anti-Cancer Therapy[electronic resource] /edited by John Pollard, Nicola Curtin. - 1st ed. 2018. - IX, 401 p. 80 illus., 52 illus. in color.online resource. - Cancer Drug Discovery and Development,2196-9906. - Cancer Drug Discovery and Development,.

1. Targeting DNA repair in anti-cancer treatments -- 2. The DNA damage response: roles in cancer etiology and treatment -- 3. Control of DNA Replication by ATR -- 4. Targeting ATR for cancer therapy: Profile & expectations for ATR inhibitors -- 5. Targeting ATR for cancer therapy: ATR-targeted drug candidates -- 6. ATM: its recruitment, activation, signalling and contribution to tumour suppression -- 7. Pre-clinical profile and expectations for pharmacological ATM inhibition -- 8. Targeting ATM for cancer therapy: Prospects for drugging ATM -- 9. Targeting Chk1 for cancer therapy: rationale, progress and prospects -- 10. Preclinical profiles and contexts for CHK1 and CHK2 inhibitors -- 11. Clinical development of CHK1 inhibitors -- 12. Established and emerging roles of the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) -- 13. Targeting DNA-PK as a therapeutic approach in oncology -- 14. Dbait: a new concept of DNA repair pathways inhibitor from bench to bedside -- 15. Alternative Non Homologous End-joining: Mechanisms and Targeting Strategies in Cancer.

Over the past decade a complex role for DNA damage response (DDR) in tumorigenesis has emerged. A proficient DDR has been shown to be a primary cause for cellular resistance to the very many DNA damaging drugs, and IR, that are widely used as standard-of-care across multiple cancer types. It has also been shown that defects in this network, predominantly within the ATM mediated signaling pathway, are commonly observed in cancers and may be a primary event during tumorigenesis. Such defects may promote a genomically unstable environment, facilitating the persistence of mutations, any of which may provide a growth or survival advantage to the developing tumor. In addition, these somatic defects provide opportunities to exploit a reliance on remaining repair pathways for survival, a process which has been termed synthetic lethality. As a result of all these observations there has been a great interest in targeting the DDR to provide anti-cancer agents that may have benefit as monotherapy in cancers with high background DNA damage levels or as a means to increase the efficacy of DNA damaging drugs and IR. In this book we will review a series of important topics that are of great interest to a broad range of academic, industrial and clinical researchers, including the basic science of the DDR, its role in tumorigenesis and in dictating response to DNA damaging drugs and IR. Additionally, we will focus on the several proteins that have been targeted in attempts to provide drug candidates, each of which appear to have quite distinct profiles and could represent very different opportunities to provide patient benefit.

ISBN: 9783319758367

Standard No.: 10.1007/978-3-319-75836-7doiSubjects--Topical Terms:

1253664
Cancer research.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Targeting the DNA Damage Response for Anti-Cancer Therapy
LDR:04133nam a22004095i 4500 001 993930
003 DE-He213
005 20200704123245.0
007 cr nn 008mamaa
008 201225s2018 gw | s |||| 0|eng d
020 $a 9783319758367 $9 978-3-319-75836-7
024 7 $a 10.1007/978-3-319-75836-7 $2 doi
035 $a 978-3-319-75836-7
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a Targeting the DNA Damage Response for Anti-Cancer Therapy $h [electronic resource] / $c edited by John Pollard, Nicola Curtin.
250 $a 1st ed. 2018.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Humana, $c 2018.
300 $a IX, 401 p. 80 illus., 52 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Cancer Drug Discovery and Development, $x 2196-9906
505 0 $a 1. Targeting DNA repair in anti-cancer treatments -- 2. The DNA damage response: roles in cancer etiology and treatment -- 3. Control of DNA Replication by ATR -- 4. Targeting ATR for cancer therapy: Profile & expectations for ATR inhibitors -- 5. Targeting ATR for cancer therapy: ATR-targeted drug candidates -- 6. ATM: its recruitment, activation, signalling and contribution to tumour suppression -- 7. Pre-clinical profile and expectations for pharmacological ATM inhibition -- 8. Targeting ATM for cancer therapy: Prospects for drugging ATM -- 9. Targeting Chk1 for cancer therapy: rationale, progress and prospects -- 10. Preclinical profiles and contexts for CHK1 and CHK2 inhibitors -- 11. Clinical development of CHK1 inhibitors -- 12. Established and emerging roles of the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) -- 13. Targeting DNA-PK as a therapeutic approach in oncology -- 14. Dbait: a new concept of DNA repair pathways inhibitor from bench to bedside -- 15. Alternative Non Homologous End-joining: Mechanisms and Targeting Strategies in Cancer.
520 $a Over the past decade a complex role for DNA damage response (DDR) in tumorigenesis has emerged. A proficient DDR has been shown to be a primary cause for cellular resistance to the very many DNA damaging drugs, and IR, that are widely used as standard-of-care across multiple cancer types. It has also been shown that defects in this network, predominantly within the ATM mediated signaling pathway, are commonly observed in cancers and may be a primary event during tumorigenesis. Such defects may promote a genomically unstable environment, facilitating the persistence of mutations, any of which may provide a growth or survival advantage to the developing tumor. In addition, these somatic defects provide opportunities to exploit a reliance on remaining repair pathways for survival, a process which has been termed synthetic lethality. As a result of all these observations there has been a great interest in targeting the DDR to provide anti-cancer agents that may have benefit as monotherapy in cancers with high background DNA damage levels or as a means to increase the efficacy of DNA damaging drugs and IR. In this book we will review a series of important topics that are of great interest to a broad range of academic, industrial and clinical researchers, including the basic science of the DDR, its role in tumorigenesis and in dictating response to DNA damaging drugs and IR. Additionally, we will focus on the several proteins that have been targeted in attempts to provide drug candidates, each of which appear to have quite distinct profiles and could represent very different opportunities to provide patient benefit.
650 0 $a Cancer research. $3 1253664
650 0 $a Gene therapy. $3 582271
650 1 4 $a Cancer Research. $3 668358
650 2 4 $a Gene Therapy. $3 580629
700 1 $a Pollard, John. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1205290
700 1 $a Curtin, Nicola. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1205291
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319758343
776 0 8 $i Printed edition: $z 9783319758350
776 0 8 $i Printed edition: $z 9783030093365
830 0 $a Cancer Drug Discovery and Development, $x 2196-9906 $3 1253870
856 4 0 $u https://doi.org/10.1007/978-3-319-75836-7
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)